Category Archives: Global News Feed

Announced launch and commercial availability of FUROSCIX® (furosemide injection), the first and only self-administered, subcutaneous loop diuretic for the at-home treatment of congestion in chronic heart failure

Read this article:
scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Business Update

NEW YORK, March 22, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ: LFMD), a leading direct-to-patient telehealth company, reported results for the fourth quarter and full year ended December 31, 2022. All figure comparisons are to the same year-ago quarter unless otherwise noted. Management will host a conference call today, March 22, 2023, at 4:30 p.m. Eastern Time to discuss the results. An updated corporate presentation and Q4 ’22 supplemental presentation were posted to https://ir.lifemd.com/#/ following the market close.

See the original post:
LifeMD, Inc. Reports Fourth Quarter/ Full Year 2022 Results; Achieves Consolidated Adjusted EBITDA Profitability

Fourth Quarter 2022 Net Revenue Increased 33% from Third Quarter 2022 While GAAP Quarter-Over-Quarter OPEX Decreased 55% and Non-GAAP OPEX Remained Unchanged

Read the original:
Agile Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Corporate Update

SAN DIEGO and SUZHOU, China and SHANGHAI, China, March 22, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in two upcoming investor conferences.

Read the original post:
Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences

Infant Bacterial Therapeutics AB (publ) publishes today the Annual Report for 2022.

More here:
Infant Bacterial Therapeutics publishes Annual Report for 2022

WALTHAM, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced the publication of research in the peer-reviewed journal Science Translational Medicine describing a model for evaluating biomarker correlates of protection for monoclonal antibodies (mAb) against symptomatic COVID-19. The research concluded that neutralizing antibodies are mechanistic in providing protection against symptomatic disease and identified serum neutralizing antibody titers as a correlate of protection. These findings have potential to support accelerated development and innovative regulatory frameworks for mAbs for prevention of COVID-19.

Read more:
Invivyd Publishes Model for Evaluating Biomarker Correlates of Protection for Monoclonal Antibodies Against Symptomatic COVID-19